Zobrazeno 1 - 10
of 37
pro vyhledávání: '"Els, Lierman"'
Autor:
Els Lierman, Sanne Smits, Niamh Appleby, Eibhlin Conneally, Lucienne Michaux, Peter Vandenberghe
Publikováno v:
HemaSphere, Vol 3, Iss 2 (2019)
Externí odkaz:
https://doaj.org/article/8d669aa02f924fe289ddcd8225038439
Publikováno v:
Acta Clinica Belgica. 77:658-663
Introduction Therapy-related myeloid neoplasms (t-MN) are frequently categorized according to previous therapy or pattern of cytogenetic abnormalities. Our objective was to evaluate and compare the mutational profile of de novo and t-MN by next gener
Publikováno v:
British journal of haematology, Vol. 200, no. 5, p. 665-668 (2022)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b5c13bd2f617082d05b7d63ade31bd56
https://hdl.handle.net/2078.1/267779
https://hdl.handle.net/2078.1/267779
Autor:
Carla Al Assaf, Florence Van Obbergh, Johan Billiet, Els Lierman, Timothy Devos, Carlos Graux, Anne-Sophie Hervent, Jan Emmerechts, Thomas Tousseyn, Pascale De Paepe, Petros Papadopoulos, Lucienne Michaux, Peter Vandenberghe
Publikováno v:
Haematologica, Vol 100, Iss 7 (2015)
The JAK2 V617F mutation, the thrombopoietin receptor MPL W515K/L mutation and calreticulin (CALR) mutations are mutually exclusive in essential thrombocythemia and support a novel molecular categorization of essential thrombocythemia. CALR mutations
Externí odkaz:
https://doaj.org/article/2a8c19fc50754382a59b6636093c52e4
Publikováno v:
Acta clinica Belgica. 77(3)
Therapy-related myeloid neoplasms (t-MN) are frequently categorized according to previous therapy or pattern of cytogenetic abnormalities. Our objective was to evaluate and compare the mutational profile ofSixty-four samples from patients with t-MN,
External quality assessment (EQA) is an essential part of performance monitoring for molecular laboratories. At the moment, a national law regulates participation in EQA schemes for clinical biology and pathology in Belgium. This study aimed (1) to g
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ba5ffcb87652aece94b9b08726699615
https://lirias.kuleuven.be/handle/123456789/644717
https://lirias.kuleuven.be/handle/123456789/644717
Publikováno v:
Haematologica, Vol 96, Iss 6 (2011)
We report a patient with T-lymphoblastic leukemia/lymphoma and a t(7;8)(q22;p11). CUX1 was identified as the fusion partner of FGFR1 by fluorescence in situ hybridization and 5′ RACE-PCR. We further investigated this novel FGFR1 fusion using the in
Externí odkaz:
https://doaj.org/article/075e6056d6444682949e07292f4e79d0
Publikováno v:
Haematologica, Vol 94, Iss 10 (2009)
Protein tyrosine kinases form a large family of signaling proteins implicated in both normal and malignant cell signaling. The aim of this study was to identify protein tyro-sine kinases that can transform hematopoietic cells to growth factor indepen
Externí odkaz:
https://doaj.org/article/882ac081c3104364a26dac440f983cb0
Autor:
Els Lierman, Jan Cools
Publikováno v:
Haematologica, Vol 92, Iss 2 (2007)
Externí odkaz:
https://doaj.org/article/42d23f110e694de48610cabf51ec1f22
Publikováno v:
Haematologica, Vol 92, Iss 1 (2007)
Background and Objectives Activated tyrosine kinases are implicated in the pathogenesis of chronic and acute leukemia, and represent attractive targets for therapy. Sorafenib (BAY43-9006, Nexavar®) is a small molecule B-RAF inhibitor that is used fo
Externí odkaz:
https://doaj.org/article/6e48c5374dc74884911b27467befe122